Observational studyBreast cancer (Tokyo, Japan)2025

Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Tetsuhiro Yoshinami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.